Arkolith/Insider Trading/SPRY/Form 4

Karas Eric

Chief Commercial OfficerARS Pharmaceuticals, Inc. (SPRY) · full profile →Form 4 · filed Jul 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$255K
Net Open-Market Flow
-$255K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2025Option exercise(M)15K$1.50$23K25K
Jul 1, 2025Sell(S)15K$16.99$255K10K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2025Option exercise(M)15K—$0545K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-019321) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML